Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,838 | 0,869 | 19:31 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | Cereno Scientific shares that the top-line results of the CS014 Phase I trial will be communicated in mid-July | 3 | Cision News | ||
23.06. | Cereno Scientific - Improved liquidity with latest debt financing | 213 | Edison Investment Research | Cereno Scientific has bolstered its liquidity position through a SEK25m loan facility secured from new Danish investors Venusat and SAJ Finans. Concurrently, the company executed an addendum to its... ► Artikel lesen | |
20.06. | Cereno Scientific secures 100 MSEK through additional loan financing and conversion to advance HDAC inhibitors CS1 and CS014 in Phase II | 1 | Cision News | ||
17.06. | Cereno Scientific - Four-month EAP data support CS1 plans | 241 | Edison Investment Research | Cereno Scientific has announced encouraging four-month follow-up data from its Expanded Access Program (EAP) for CS1, a first-in-class HDAC inhibitor being developed to treat pulmonary arterial hypertension... ► Artikel lesen | |
16.06. | Cereno Scientific AB: Cereno Scientific shares 4-month follow-up data from Expanded Access Program in line with Phase IIa trial results of CS1 in rare disease PAH | 98 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced 4-month... ► Artikel lesen | |
10.06. | Cereno Scientific AB: Cereno Scientific shares the report from Annual General Meeting 2025 | 147 | GlobeNewswire (Europe) | Today, June 10, 2025 Cereno Scientific AB (publ) held Annual General Meeting at the MAQS Advokatbyrå's premises at Masthamnsgatan 13 in Gothenburg, Sweden. Chairman of the Annual General Meeting (the... ► Artikel lesen | |
27.05. | Cereno Scientific - Firing on all cylinders | 328 | Edison Investment Research | In Q125, Cereno made tangible progress across both its clinical programmes. The period opened with new data for lead asset CS1 indicating disease-modifying signals, and was capped by FDA endorsement... ► Artikel lesen | |
CERENO SCIENTIFIC Aktie jetzt für 0€ handeln | |||||
27.05. | Cereno Scientific is nominated and shortlisted for 'Company of the Year' in the European Mediscience Awards 2025 | 1 | Cision News | ||
23.05. | Cereno Scientific AB: Cereno Scientific receives endorsement from FDA on plans for Phase IIb trial of CS1 in rare disease pulmonary arterial hypertension (PAH) | 134 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
22.05. | Cereno Scientific AB: Cereno Scientific publishes Interim Report for Q1 2025 (January 1 - March 31, 2025) | 190 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
15.05. | Cereno Scientific publishes Annual Report for 2024 | 1 | Cision News | ||
13.05. | Cereno Scientific presented CS1's Phase IIa trial results at the 5th Baltic Pulmonary Hypertension Conference 2025 | 2 | Cision News | ||
09.05. | Cereno Scientific give notice to attend the Annual General Meeting 2025 | 1 | Cision News | ||
07.05. | Correction: Cereno Scientific's Nomination Committee proposes new Board with M&A profile ahead of the Annual General Meeting on June 10, 2025 | 1 | Cision News | ||
07.05. | Cereno Scientific's Nomination Committee proposes new Board with M&A profile ahead of the Annual General Meeting on May 10, 2025 | 2 | Cision News | ||
07.05. | Cereno Scientific to present at ABGSC Investor Days on May 13-14, 2025, in Stockholm | 1 | Cision News | ||
23.04. | Cereno Scientific - CS1 takes another step towards Phase IIb | 304 | Edison Investment Research | Cereno Scientific has successfully completed its planned Type C meeting with the FDA for lead asset CS1. The minutes from the meeting will be available after 30 days, but Cereno has indicated that the... ► Artikel lesen | |
22.04. | Cereno Scientific aligns with FDA on CS1 development | 3 | Cision News | ||
22.04. | Cereno Scientific AB: Cereno Scientific completes successful FDA meeting discussing further clinical development of drug candidate CS1 in rare disease PAH | 183 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
17.04. | Cereno Scientific - CS014 completes Phase I, path clears for Phase II | 382 | Edison Investment Research | Cereno Scientific has announced that its second clinical stage asset, CS014, has completed the Phase I safety study, with the conclusion of the second, multiple ascending dose (MAD) part of the trial... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 40,740 | -1,31 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
EVOTEC | 7,350 | +1,38 % | Übernahmefieber! BioTech und Künstliche Intelligenz beflügelt Evotec, NetraMark Holdings, NovoNordisk und Bayer | Derzeit erlebt der Biotech-Sektor eine spannende Transformation: Denn Big Data und Künstliche Intelligenz verändern in rasanter Art und Weise, wie neue Medikamente entdeckt, entwickelt und getestet... ► Artikel lesen | |
BEAM THERAPEUTICS | 19,260 | +10,06 % | H.C. Wainwright bekräftigt Kaufempfehlung für Beam Therapeutics mit Kursziel von 80 US-Dollar | ||
BIONTECH | 91,10 | -0,11 % | BioNTech schluckt CureVac! Evotec und Vidac als nächstes? Kurstreiber Übernahme und Kaufempfehlung | Steht bei Vidac Pharma eine neue Kursexplosion bevor? Im vergangenen Herbst ging es um rund 200 % nach oben. Gestern gab es eine Kaufempfehlung. Die Analysten sehen bei der Biotech-Perle Vervielfachungspotenzial.... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 22,290 | +5,14 % | Revolution Medicines, Inc.: Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors | REDWOOD CITY, Calif. and MIAMI, June 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,205 | +1,46 % | Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process? | ||
VOR BIOPHARMA | 1,470 | +3,16 % | Vor Biopharma: Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective... ► Artikel lesen | |
MODERNA | 25,750 | +5,64 % | Code des Lebens entschlüsselt - so geht es weiter! Illumina, PanGenomic Health, Moderna | Erbinformationen sind die Baupläne des Lebens. Schon heute lassen sich mit Hilfe der Genomsequenzierung Informationen gewinnen, die unser Leben verlängern. Das gilt etwa, wenn wir bestimmte Vorprägungen... ► Artikel lesen | |
ONCO-INNOVATIONS | 1,250 | -16,11 % | CEO von Onco-Innovations hält am Mittwoch, den 2. Juli 2025 eine Sondertelefonkonferenz für Investoren ab | Vancouver, Kanada - 25. Juni 2025 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" oder das "Unternehmen") freut sich bekannt zu geben... ► Artikel lesen | |
ARRIVENT BIOPHARMA | 20,775 | -0,46 % | ArriVent BioPharma prices $75M equity offering | ||
REGENCELL BIOSCIENCE | 10,540 | -27,81 % | Fair-Value-Alarm erfasst 60% Kursrückgang bei Regencell Bioscience-Aktie | ||
VERVE THERAPEUTICS | 11,310 | +0,27 % | BMO downgrades Verve Therapeutics saying Lilly buyout deal caps upside | ||
PRIME MEDICINE | 3,240 | +18,46 % | Prime Medicine, Inc.: Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition | -- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or... ► Artikel lesen | |
CUREVAC | 4,594 | +0,26 % | CureVac mit EILMELDUNG: Eigener Vorstand kauft massiv Anteile - Aus diesem Grund müssen Sie SOFORT reagieren! | ||
KYMERA THERAPEUTICS | 44,820 | +0,90 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen |